LGALS3 and congenital heart disease: In previous studies, Gal-3 has been studied as a biomarker of fibrosis with a prognostic role in HF mortality and rehospitalization and in congenital heart disease patients as a prognostic indicator in risk stratification [21,27,28,29,30,31,32].